Every one of those 1 sits in a single category, market-trends. Compass Pathways is most often covered alongside COMP360, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 5.8 in the same window.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Compass Pathways
Every one of those 1 sits in a single category, market-trends. Compass Pathways is most often covered alongside COMP360, which appears in 1 of these 1 story. The 5 average consequence score is below the beat benchmark of 5.8 in the same window. Each story carries 2 original sources on average, compared with 2.4 for the broader beat in this window. We currently track 1 Healthcare story that mention Compass Pathways, all published on March 24, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 29 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Compass Pathways. Shared-story counts are live from our verified record — not editorial picks.
Compass Pathways reported its full-year 2025 financial results, highlighting a strategic focus on its pivotal Phase 3 COMP360 program for treatment-resistant depression. With a cash runway extending into late 2026, the company is positioned for a critical year of clinical readouts and regulatory engagement.